Last reviewed · How we verify
Intermediate metabolisers — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intermediate metabolisers (Intermediate metabolisers) — Radboud University Medical Center. Intermediate metabolisers is not a drug but a pharmacogenetic classification describing individuals with moderate capacity to metabolize certain medications via cytochrome P450 enzymes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intermediate metabolisers TARGET | Intermediate metabolisers | Radboud University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intermediate metabolisers CI watch — RSS
- Intermediate metabolisers CI watch — Atom
- Intermediate metabolisers CI watch — JSON
- Intermediate metabolisers alone — RSS
Cite this brief
Drug Landscape (2026). Intermediate metabolisers — Competitive Intelligence Brief. https://druglandscape.com/ci/intermediate-metabolisers. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab